Xenon Pharmaceuticals Inc.
XENENASDAQHealthcare● Active
$51.31
$-0.42(-0.82%)
Market Cap$4.1B
P/E Ratio—
52W High$63.95
52W Low$30
Xenon Pharmaceuticals Inc. (XENE) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · XENE · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $7.50M | $0.00M | $0.00M | $9.43M | $18.44M |
| Cost of Revenue | $2.54M | $2.56M | $167.51M | $0.00M | $0.00M |
| Gross Profit | $4.96M | ($2.56M) | ($167.51M) | $9.43M | $18.44M |
| Gross Margin %(computed) | 66.09% | — | — | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $300.94M | $210.39M | $167.51M | $105.77M | $75.46M |
| G&A Expenses | $79.63M | $68.90M | $46.54M | $32.81M | $21.97M |
| Total Operating Expenses | $378.03M | $276.74M | $46.54M | $138.58M | $97.43M |
| Operating Income | ($373.07M) | ($279.30M) | ($214.05M) | ($129.14M) | ($78.99M) |
| Operating Margin %(computed) | — | — | — | — | -428.45% |
| Interest Income | $26.83M | $41.94M | $27.62M | $8.71M | $0.47M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($344.89M) | ($238.42M) | ($182.69M) | ($125.25M) | ($78.89M) |
| Income Tax Expense | $1.02M | ($4.09M) | ($0.29M) | $0.12M | ($0.01M) |
| Net Income | ($345.91M) | ($234.33M) | ($182.39M) | ($125.37M) | ($78.88M) |
| Net Margin %(computed) | — | — | — | — | -427.85% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 |
| Wtd Avg Shares | 79.25M | 77.89M | 66.89M | 60.54M | 43.63M |
| EBITDA | ($342.35M) | ($235.86M) | ($210.51M) | ($127.74M) | ($78.09M) |
| EBITDA Margin %(computed) | — | — | — | — | -423.53% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Xenon Pharmaceuticals Inc. data
About Xenon Pharmaceuticals Inc. (XENE) Income Statement
Xenon Pharmaceuticals Inc. (XENE) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, XENE reported revenue of $0.01B, gross profit of $0.00B (gross margin 66.09%), and net income of ($0.35B) — a net profit margin of -4612.13%.
Frequently asked questions
XENE · 4 questionsXenon Pharmaceuticals Inc. (XENE) reported revenue of $0.01B for 2025, up —% year-over-year.
XENE revenueXENE salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08